Scancell Holdings Share Price | |
---|---|
Price | 10.00 |
Bid | 9.50 |
Ask | 10.50 |
Change | 0.25 (2.56%) |
Volume | 70,659 |
Open | 9.75 |
High | 10.00 |
Low | 9.75 |
Prev. Close | 9.75 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 928.98m |
Market Capitalisation | £92.90m |
Market Size | 30,000 |
52 Week High | 17.375 |
52 Week High Date | 20-Sep-2023 |
52 Week Low | 7.65 |
52 Week Low Date | 05-Sep-2023 |
# Trades | 4 |
---|---|
Vol. Sold | 563 |
Sold Value | £N/A |
Vol. Bought | 70,096 |
Bought Value | £7.01k |
PE Ratio | -6.669334 |
Earnings | -1.4994 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
21-Jun-24 | 14:31:32 | 10.40 | 96 | Buy* | 9.50 | 10.50 | 9.98 | O Ordinary |
21-Jun-24 | 12:49:35 | 9.50 | 485 | Sell* | 9.50 | 10.50 | 46.08 | O Ordinary Trade was executed as an SI |
21-Jun-24 | 12:49:35 | 9.50 | 78 | Sell* | 9.50 | 10.50 | 7.41 | O Ordinary Trade was executed as an SI |
21-Jun-24 | 12:49:30 | 10.00 | 70,000 | Buy* | 9.50 | 10.00 | 7,000 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
06-Dec-23 | 05-Dec-23 | Buy | Lindy Durrant held the position of CEO at the time of this trade.Lindy Durrant | 11.00 | GBX | 272,727 | 272,727 |
06-Dec-23 | 05-Dec-23 | Buy | Jean-Michel Cosséry held the position of Non-Executive Chairman at the time of this trade.Jean-Michel Cosséry | 11.00 | GBX | 454,545 | 454,545 |
03-Mar-22 | 02-Mar-22 | Buy | Martin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle | 12.00 | GBX | 250,000 | 117,729,029 |
03-Nov-21 | 02-Nov-21 | Buy | Martin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle | 19.00 | GBX | 200,000 | 118,479,029 |
02-Nov-21 | 29-Oct-21 | Buy | Martin Diggle held the position of Non-Executive Director at the time of this trade.Martin Diggle | 19.00 | GBX | 100,000 | 118,279,029 |
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.